Po-Chun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Po-Chun Chen has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Anke Renate Maria Kraft
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications - Heiner Wedemeyer
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications - Markus Cornberg
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications - Niklas K. Björkström
Center for Infectious Medicine Department of Medicine Huddinge Karolinska Institutet Karolinska University Hospital Stockholm Sweden
2 shared publications - Norman Woller
Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
2 shared publications - Sophie Anna Engelskircher
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
2 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (7) , e0415825
Impact of deubiquitination of Epstein-Barr virus Rta and Zta on lytic development
Rta and Zta are transcription factors expressed by Epstein-Barr virus (EBV) during the immediate-early stage of the lytic cycle. While these two proteins do not interact directly, they bind to a scaffold protein, RanBPM, to synergistically activate the transcription of EBV lytic genes. Earlier studies have shown that both Rta and Zta are destabilized through ubiquitination, which plays a crucial role in influencing EBV’s lytic development. It is also known that Rta’s ubiquitination is facilitated by the ubiquitin E3 ligase, RNF4. In this study, we show that RNF4 also promotes the ubiquitination of Zta. Meanwhile, a deubiquitinase, ubiquitin-specific protease (USP11), is known to interact with RanBPM. When tethered to RanBPM, Rta and Zta are deubiquitinated and stabilized by USP11. While host cells may utilize ubiquitination as a defense mechanism to destabilize Rta and Zta, thereby restricting EBV proliferation, EBV exploits RanBPM and the deubiquitination of Rta and Zta as a counter-defense strategy that favors EBV lytic replication. This study uncovers the interplay between the host and the viral mechanisms involving RNF4 and USP11 in modulating EBV lytic progression. IMPORTANCE: Epstein-Barr virus (EBV) is known to express two crucial transcription factors, Rta and Zta, which are essential for activating the transcription of viral lytic genes. These two proteins are indispensable for viral lytic proliferation. While Rta and Zta can function independently to promote transcription, they also cooperate synergistically, leading to robust expression of EBV lytic proteins. In an earlier study, we showed that this synergy requires the formation of a complex involving Rta, Zta, and RanBPM at the Zta response elements in EBV lytic promoters. Recent studies showed that, despite their importance, these transcription factors are destabilized by ubiquitination, potentially serving as a mechanism through which the host restricts EBV proliferation. This study shows that EBV exploits USP11, which interacts with RanBPM, to deubiquitinate and stabilize Rta and Zta. The stabilization by USP11 is critical for EBV to overcome host-imposed restrictions and maximize its lytic proliferation.
- 7 July 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (7) , e0415825
Open AccessImpact of deubiquitination of Epstein-Barr virus Rta and Zta on lytic development
Rta and Zta are transcription factors expressed by Epstein-Barr virus (EBV) during the immediate-early stage of the lytic cycle. While these two proteins do not interact directly, they bind to a scaffold protein, RanBPM, to synergistically activate the transcription of EBV lytic genes. Earlier studies have shown that both Rta and Zta are destabilized through ubiquitination, which plays a crucial role in influencing EBV’s lytic development. It is also known that Rta’s ubiquitination is facilitated by the ubiquitin E3 ligase, RNF4. In this study, we show that RNF4 also promotes the ubiquitination of Zta. Meanwhile, a deubiquitinase, ubiquitin-specific protease (USP11), is known to interact with RanBPM. When tethered to RanBPM, Rta and Zta are deubiquitinated and stabilized by USP11. While host cells may utilize ubiquitination as a defense mechanism to destabilize Rta and Zta, thereby restricting EBV proliferation, EBV exploits RanBPM and the deubiquitination of Rta and Zta as a counter-defense strategy that favors EBV lytic replication. This study uncovers the interplay between the host and the viral mechanisms involving RNF4 and USP11 in modulating EBV lytic progression. IMPORTANCE: Epstein-Barr virus (EBV) is known to express two crucial transcription factors, Rta and Zta, which are essential for activating the transcription of viral lytic genes. These two proteins are indispensable for viral lytic proliferation. While Rta and Zta can function independently to promote transcription, they also cooperate synergistically, leading to robust expression of EBV lytic proteins. In an earlier study, we showed that this synergy requires the formation of a complex involving Rta, Zta, and RanBPM at the Zta response elements in EBV lytic promoters. Recent studies showed that, despite their importance, these transcription factors are destabilized by ubiquitination, potentially serving as a mechanism through which the host restricts EBV proliferation. This study shows that EBV exploits USP11, which interacts with RanBPM, to deubiquitinate and stabilize Rta and Zta. The stabilization by USP11 is critical for EBV to overcome host-imposed restrictions and maximize its lytic proliferation.
- Open Access
- 23 January 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (6) , 1565-1581
TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D
Background and Aims: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV treatment may influence immune cells in patients with CHD and performed a high-resolution analysis of natural killer (NK) cells before and during BLV therapy. Approach and Results: BLV-treated patients with CHD (n=20) from a single-center cohort were longitudinally analyzed for clinical, molecular, and virological parameters. Peripheral blood mononuclear cells were studied at baseline, and therapy weeks 3 and 48 by spectral flow cytometry. Healthy donors, patients with chronic hepatitis C after direct-acting antiviral treatment, and patients with chronic hepatitis B were used as controls. Overall, NK cell frequencies remained stable during BLV treatment. However, biochemical responders showed distinct NK cell immunophenotypic features before and during therapy. TIGIT expression increased on CD56 dim and CD56 bright NK cells during the course of BLV treatment and inversely correlated with ALT levels in CHD but not patients with CHC or CHB. High frequencies of TIGIT − CD57 + CD56 dim NK cells at baseline and low levels during therapy were indicative of a biochemical response. Conclusions: We here suggest that lacking the expression of the immune checkpoint inhibitor TIGIT on NK cell subtypes may be a hallmark of liver inflammation in HDV infection. BLV therapy is associated with a reappearance of TIGIT on these cells, which may be one mechanism of why liver enzymes rapidly improve during therapy.
- 23 January 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 82 (6) , 1565-1581
Open AccessTIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D
Background and Aims: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV treatment may influence immune cells in patients with CHD and performed a high-resolution analysis of natural killer (NK) cells before and during BLV therapy. Approach and Results: BLV-treated patients with CHD (n=20) from a single-center cohort were longitudinally analyzed for clinical, molecular, and virological parameters. Peripheral blood mononuclear cells were studied at baseline, and therapy weeks 3 and 48 by spectral flow cytometry. Healthy donors, patients with chronic hepatitis C after direct-acting antiviral treatment, and patients with chronic hepatitis B were used as controls. Overall, NK cell frequencies remained stable during BLV treatment. However, biochemical responders showed distinct NK cell immunophenotypic features before and during therapy. TIGIT expression increased on CD56 dim and CD56 bright NK cells during the course of BLV treatment and inversely correlated with ALT levels in CHD but not patients with CHC or CHB. High frequencies of TIGIT − CD57 + CD56 dim NK cells at baseline and low levels during therapy were indicative of a biochemical response. Conclusions: We here suggest that lacking the expression of the immune checkpoint inhibitor TIGIT on NK cell subtypes may be a hallmark of liver inflammation in HDV infection. BLV therapy is associated with a reappearance of TIGIT on these cells, which may be one mechanism of why liver enzymes rapidly improve during therapy.
- Open Access
- 20 February 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (1) , 202-222
Impending HCC diagnosis in patients with cirrhosis after HCV cure features a natural killer cell signature
Background and Aims: The risk of developing HCC in chronically infected patients with AQ2 HCV with liver cirrhosis is significantly elevated. This risk remains high even after a sustained virological response with direct-acting antivirals. To date, disease-associated signatures of NK cells indicating HCC development are unclear. Approach and Results: This study investigated NK cell signatures and functions in 8 cohorts covering the time span of HCC development, diagnosis, and onset. In-depth analysis of NK cell profiles from patients with cirrhosis who developed HCC (HCV-HCC) after sustained virological response compared with those who remained tumor-free (HCV-noHCC) revealed increasingly dissimilar NK cell signatures over time. We identified expression patterns with persistently high frequencies of TIM-3 and CD38 on NK cells that were largely absent in healthy controls and were associated with a high probability of HCC development. Functional assays revealed that the NK cells had potent cytotoxic features. In contrast to HCV-HCC, the signature of HCV-noHCC converged with the signature found in healthy controls over time. Regarding tissue distribution, single-cell sequencing showed high frequencies of these cells in liver tissue and the invasive margin but markedly lower frequencies in tumors Conclusions: We show that HCV-related HCC development has profound effects on the imprint of NK cells. Persistent co-expression of TIM-3hi and CD38+ on NK cells is an early indicator for HCV-related HCC development. We propose that the profiling of NK cells may be a rapid and valuable tool to assess the risk of HCC development in a timely manner in patients with cirrhosis after HCV cure.
- 20 February 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 80 (1) , 202-222
Open AccessImpending HCC diagnosis in patients with cirrhosis after HCV cure features a natural killer cell signature
Background and Aims: The risk of developing HCC in chronically infected patients with AQ2 HCV with liver cirrhosis is significantly elevated. This risk remains high even after a sustained virological response with direct-acting antivirals. To date, disease-associated signatures of NK cells indicating HCC development are unclear. Approach and Results: This study investigated NK cell signatures and functions in 8 cohorts covering the time span of HCC development, diagnosis, and onset. In-depth analysis of NK cell profiles from patients with cirrhosis who developed HCC (HCV-HCC) after sustained virological response compared with those who remained tumor-free (HCV-noHCC) revealed increasingly dissimilar NK cell signatures over time. We identified expression patterns with persistently high frequencies of TIM-3 and CD38 on NK cells that were largely absent in healthy controls and were associated with a high probability of HCC development. Functional assays revealed that the NK cells had potent cytotoxic features. In contrast to HCV-HCC, the signature of HCV-noHCC converged with the signature found in healthy controls over time. Regarding tissue distribution, single-cell sequencing showed high frequencies of these cells in liver tissue and the invasive margin but markedly lower frequencies in tumors Conclusions: We show that HCV-related HCC development has profound effects on the imprint of NK cells. Persistent co-expression of TIM-3hi and CD38+ on NK cells is an early indicator for HCV-related HCC development. We propose that the profiling of NK cells may be a rapid and valuable tool to assess the risk of HCC development in a timely manner in patients with cirrhosis after HCV cure.
- 1 January 2021
- Published by Elsevier
Contributors